Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2023

Open Access 01-12-2023 | NSCLC | Research

The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer

Authors: Minxia Zhu, Shaomin Li, Liyue Yuan, Shiyuan Liu, Jianzhong Li, Danjie Zhang, Jia Chen, Jiantao Jiang, Zhengshui Xu

Published in: World Journal of Surgical Oncology | Issue 1/2023

Login to get access

Abstract

Objectives

Although postoperative radiotherapy (PORT) could reduce the incidence of local recurrence in patients with IIIA-N2 non-small cell lung cancer (NSCLC), the role of PORT on survival in patients with surgically treated stage IIIA-N2 NSCLC remains controversial. Therefore, this study was designed to evaluate the effect of PORT on survival for patients with surgically treated stage IIIA-N2 NSCLC.

Materials and methods

This study population was chosen from the Surveillance, Epidemiology, and End Results database. The Cox proportional hazards regression analysis was used to determine significant contributors to overall survival (OS) and cancer special survival (CSS) outcomes. To balance baseline characteristics between the non-PORT group and PORT group, propensity score matching (PSM) with 1:1 propensity nearest-neighbor match by 0.001 matching tolerance was conducted by R software. Furthermore, a Kaplan–Meier curve was used to visualize the OS and CSS between the PORT group and non-PORT group survival probability.

Results

Of all evaluated cases, 4511 with IIIA-N2 NSCLC were eligible for inclusion, of which 1920 were enrolled into the PORT group. On univariate analysis and multivariate analysis, sex, age, year of diagnosis, race, histologic type, T stage, PORT, use of chemotherapy, and positive regional nodes were significantly associated with OS and CSS in IIIA-N2 NSCLC (P < 0.05). However, PORT was not significantly associated with OS (univariate HR = 0.92, 95%CI 0.85–0.99, P = 0.02; multivariate HR = 1.01, 95%CI 0.93–1.08, P = 0.91) and CSS (univariate HR = 0.92, 95%CI 0.85–1.01, P = 0.06; multivariate HR = 1.103 95%CI 0.94–1.12, P = 0.56) in IIIA-N2 NSCLC. Meanwhile, after PSM, neither OS nor CSS did differ significantly between the non-PORT group and PORT group (OS HR = 1.08, 95%CI 0.98–1.19, P = 0.12; CSS HR = 1.10, 95%CI 0.99–1.23, P = 0.07).

Conclusion

PORT did not contribute to a survival benefit in patients with surgically treated stage IIIA-N2 NSCLC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.CrossRefPubMed Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.CrossRefPubMed
3.
go back to reference Liu J, Ladbury C, Kim J, et al. Postoperative radiation therapy should be used for completely resected stage III-N2 NSCLC in select patients. J Thorac Oncol. 2022;17(2):194–6.CrossRefPubMed Liu J, Ladbury C, Kim J, et al. Postoperative radiation therapy should be used for completely resected stage III-N2 NSCLC in select patients. J Thorac Oncol. 2022;17(2):194–6.CrossRefPubMed
4.
go back to reference Faivre-Finn C, Edwards JG, Hatton M. Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC. J Thorac Oncol. 2022;17(2):197–9.CrossRefPubMed Faivre-Finn C, Edwards JG, Hatton M. Postoperative Radiation Therapy Should Not Be Used for the Therapy of Stage III-N2 NSCLC. J Thorac Oncol. 2022;17(2):197–9.CrossRefPubMed
5.
go back to reference Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial. JAMA Oncol. 2021;7(8):1178–85.CrossRefPubMed Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial. JAMA Oncol. 2021;7(8):1178–85.CrossRefPubMed
6.
go back to reference Zhu L, Xia B, Ma S. Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out. Thorac Cancer. 2022;13(5):659–63.CrossRefPubMedPubMedCentral Zhu L, Xia B, Ma S. Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out. Thorac Cancer. 2022;13(5):659–63.CrossRefPubMedPubMedCentral
7.
go back to reference Lei T, Li J, Zhong H, et al. Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11: 680615.CrossRefPubMedPubMedCentral Lei T, Li J, Zhong H, et al. Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11: 680615.CrossRefPubMedPubMedCentral
8.
go back to reference Yamasaki N, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Role of postoperative radiotherapy in patients with completely resected pIIIA-N2 non-small cell lung cancer. Clin Lung Cancer. 2022;23(3):e171–2.CrossRefPubMed Yamasaki N, Kim YH, Iwatsubo S, Nishimura Y, Funada Y. Role of postoperative radiotherapy in patients with completely resected pIIIA-N2 non-small cell lung cancer. Clin Lung Cancer. 2022;23(3):e171–2.CrossRefPubMed
9.
go back to reference Sun X, Men Y, Wang J, et al. Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Thorac Cancer. 2021;12(9):1358–65.CrossRefPubMedPubMedCentral Sun X, Men Y, Wang J, et al. Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Thorac Cancer. 2021;12(9):1358–65.CrossRefPubMedPubMedCentral
10.
go back to reference Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. Springer International Publishing; 2017. p. 431–56. Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual. 8th ed. Springer International Publishing2017. p. 431–56.
11.
go back to reference Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):492–9.CrossRefPubMed Bekelman JE, Rosenzweig KE, Bach PB, Schrag D. Trends in the use of postoperative radiotherapy for resected non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66(2):492–9.CrossRefPubMed
12.
go back to reference Xu L, Xie HN, Chen XK, Bi N, Qin JJ, Li Y. Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non-small cell lung cancer: A population-based study. Thorac Cancer. 2021;12(6):760–7.CrossRefPubMedPubMedCentral Xu L, Xie HN, Chen XK, Bi N, Qin JJ, Li Y. Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non-small cell lung cancer: A population-based study. Thorac Cancer. 2021;12(6):760–7.CrossRefPubMedPubMedCentral
13.
go back to reference Wang SF, Mao NQ, Zhao WH, Pan XB. Postoperative radiotherapy in pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: A meta-analysis. Medicine (Baltimore). 2022;101(28): e29550.CrossRefPubMed Wang SF, Mao NQ, Zhao WH, Pan XB. Postoperative radiotherapy in pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: A meta-analysis. Medicine (Baltimore). 2022;101(28): e29550.CrossRefPubMed
14.
go back to reference Wang X, Song J, Long J, Zeng Z, Liu A. Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. Radiat Oncol. 2021;16(1):184.CrossRefPubMedPubMedCentral Wang X, Song J, Long J, Zeng Z, Liu A. Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database. Radiat Oncol. 2021;16(1):184.CrossRefPubMedPubMedCentral
15.
go back to reference Duan H, Liang L, Xie S, Wang C. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study. BMC Cancer. 2020;20(1):809.CrossRefPubMedPubMedCentral Duan H, Liang L, Xie S, Wang C. The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study. BMC Cancer. 2020;20(1):809.CrossRefPubMedPubMedCentral
16.
go back to reference Gao F, Li N, Xu Y, Yang G. Evaluation of postoperative radiotherapy effect on survival of resected stage III-N2 non-small cell lung cancer patients. Front Oncol. 2020;10:1135.CrossRefPubMedPubMedCentral Gao F, Li N, Xu Y, Yang G. Evaluation of postoperative radiotherapy effect on survival of resected stage III-N2 non-small cell lung cancer patients. Front Oncol. 2020;10:1135.CrossRefPubMedPubMedCentral
17.
go back to reference Wang S, Ma Z, Yang X, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol. 2017;12(1):207.CrossRefPubMedPubMedCentral Wang S, Ma Z, Yang X, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol. 2017;12(1):207.CrossRefPubMedPubMedCentral
18.
go back to reference Zarinshenas R, Ladbury C, McGee H, et al. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022;173:10–8.CrossRefPubMed Zarinshenas R, Ladbury C, McGee H, et al. Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer. Radiother Oncol. 2022;173:10–8.CrossRefPubMed
19.
go back to reference Allaeys T, Berzenji L, Lauwers P, et al. Multimodality treatment including surgery related to the type of N2 involvement in locally advanced non-small cell lung cancer. Cancers (Basel). 2022;14(7):1656. Allaeys T, Berzenji L, Lauwers P, et al. Multimodality treatment including surgery related to the type of N2 involvement in locally advanced non-small cell lung cancer. Cancers (Basel). 2022;14(7):1656.
20.
go back to reference Zhang CC, Hou RP, Xia WY, et al. Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study. Lung Cancer. 2021;156:100–8.CrossRefPubMed Zhang CC, Hou RP, Xia WY, et al. Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study. Lung Cancer. 2021;156:100–8.CrossRefPubMed
21.
go back to reference Zeng WQ, Feng W, Xie L, et al. Postoperative radiotherapy for resected stage IIIA-N2 non-small-cell lung cancer: a population-based time-trend study. Lung. 2019;197(6):741–51.CrossRefPubMed Zeng WQ, Feng W, Xie L, et al. Postoperative radiotherapy for resected stage IIIA-N2 non-small-cell lung cancer: a population-based time-trend study. Lung. 2019;197(6):741–51.CrossRefPubMed
22.
go back to reference Zhang CC, Yu W, Zhang Q, Cai XW, Feng W, Fu XL. A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. Radiother Oncol. 2022;173:313–8.CrossRefPubMed Zhang CC, Yu W, Zhang Q, Cai XW, Feng W, Fu XL. A decision support framework for postoperative radiotherapy in patients with pathological N2 non-small cell lung cancer. Radiother Oncol. 2022;173:313–8.CrossRefPubMed
23.
go back to reference Bertoglio P, Ricciardi S, Alì G, et al. N2 lung cancer is not all the same: an analysis of different prognostic groups. Interact Cardiovasc Thorac Surg. 2018;27(5):720–6.CrossRefPubMed Bertoglio P, Ricciardi S, Alì G, et al. N2 lung cancer is not all the same: an analysis of different prognostic groups. Interact Cardiovasc Thorac Surg. 2018;27(5):720–6.CrossRefPubMed
24.
go back to reference Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(12):1675–84.CrossRefPubMed Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2015;10(12):1675–84.CrossRefPubMed
Metadata
Title
The high-risk features and effect of postoperative radiotherapy on survival for patients with surgically treated stage IIIA-N2 non-small cell lung cancer
Authors
Minxia Zhu
Shaomin Li
Liyue Yuan
Shiyuan Liu
Jianzhong Li
Danjie Zhang
Jia Chen
Jiantao Jiang
Zhengshui Xu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2023
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-023-03093-8

Other articles of this Issue 1/2023

World Journal of Surgical Oncology 1/2023 Go to the issue